Hagens Berman Reminds MannKind Corp. (NASDAQGM: MNKD) Investors of March 15, 2016 Lead Plaintiff Deadline in a Class Action Lawsuit

SAN FRANCISCO, March 09, 2016 -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors in MannKind Corp. (NASDAQ:MNKD) that there is a March 15, 2016 lead plaintiff deadline in the class action related to undisclosed issues impeding sales of its flagship insulin inhalant, Afrezza.  

If you suffered losses greater than $500,000 or held more than 100,000 shares on January 5, 2016 from purchases of MannKind securities between August 10, 2015 and January 5, 2016, or have information that will help our investigation contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation by calling 510-725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/MNKD.  The lawsuit was filed in the U.S. District Court for the Central District of California and investors have until March 15, 2016 to move the court to participate as a lead plaintiff.

MannKind, is a biopharmaceutical company whose main product, Afrezza, is a rapid-acting insulin inhaled at mealtimes to help control insulin levels in adults with type 1 and type 2 diabetes.  On January 5, 2016, MannKind issued a press release announcing the termination of its license and collaboration agreement with pharmaceutical distributor Sanofi-Aventis. That same day, Bloomberg reported that the agreement was terminated due to low level of prescriptions despite Sanofi's best efforts. On this news, the company's stock fell $0.70 per share, or over 48%, to close at $0.75 per share on January 5, 2016.

Then, on January 6, 2016, an article published in the LA Times stated that Afrezza was unsuccessful because the doctors tasked with carrying out FDA-mandated lung testing on Afrezza patients were unfamiliar with the tests, and didn’t prescribe Afrezza as a result. On this news, the company's stock fell further, by approximately 2.67%, to close at $0.73 per share on January 6, 2016.

The complaint alleges that defendants misled investors by failing to disclose that, in spite of MannKind’s assurances, the FDA’s required testing was impeding sales of Afrezza. As a result, their statements throughout the class period were false and / or misleading and lacked a reasonable basis, in violation of the securities laws.

Whistleblowers: Persons with non-public information regarding MannKind should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].

About Hagens Berman
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000